Funding opportunities and RFIs to support research relating to COVID-19 from various agencies/organizations are listed below; please note that this list is not exhaustive. The list will be updated Mondays, Wednesdays, and Fridays by 4 pm. Please contact [email protected] to add a funding opportunity or with any questions.

Proposals for critical continuing laboratory research that could impact the diagnosis or treatment of COVID-19 in the current crisis should be sent to [email protected] for review and approval. 

Title

Organization

Amount

Deadlines

Discipline

Description

Date Posted

Notice of Special Interest (NOSI): Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19)

NIH (NIAID)

Not specified

4/5/20; varies by program

Biomedical

NIAID is offering Competitive Revisions to active grants and funding for new projects. Viral natural history, pathogenicity, transmission, medical countermeasures, animal models, pre-clinical testing of vaccines and therapeutics.

3/27/20

LifeArc COVID-19 Fund: Coronavirus (COVID-19) therapeutics

LifeArc

10 M GBP (total funding available)

4/6/20

Biomedical

Clinical research, Drug Development, Therapeutics

3/20/20

Dear Colleague Letter: Request for SBIR/STTR Phase I Proposals Addressing COVID-19

NSF

Not specified

rolling

Technology development, Biomedical, Physical Sciences, Computation, Engineering

artificial intelligence, digital health, diagnostics, distributed ledger, environmental technologies, medical devices, pharmaceutical technologies, disinfection and sterilization, filtration and separations

3/25/20

Notice of Special Interest (NOSI): Clinical and Translational Science Award (CTSA) Program Applications to Address 2019 Novel Coronavirus (COVID-19) Public Heath Needt

NIH

Not Specified

5/4/20, 7/10/20; varies by program

Biomedical, Public Health

NCATS is offering Supplements to certain active grants to study the use of informatics solutions to diagnose cases and the use of CTSA-supported core resources to facilitate research on COVID-19 and advance the translation of research findings into diagnostics, therapeutics, and vaccines.

3/24/20

COVID-19 Broad Agency Announcement

CDC

$10 M (total funding available)

White papers due by 3:00PM EST on 3/25/20

Biomedical, Public Health

Transmission, Diagnostics development, Immune response, Antibody production, small animal model development, identify biomarkers

3/11/20

AHA Rapid Response Grant: COVID-19 and Its Cardiovascular Impact

American Heart Association

up to $100,000

4/6/20

Biomedical

Understanding the cardiovascular and cerebrovascular pathogenesis, diagnosis, prevention, clinical manifestations, clinical management (including critical care management) and social behaviors which can lead to dissemination, containment, and complications of COVID-19

3/24/20

Division of Research, Innovation & Ventures (DRIVe) Easy Broad Agency Announcement (EZ-BAA), Area of Interest (AOI) #4: COVID-19

BARDA

up to $750,000

Abstracts due by 6/30/20

Biomedical, Devices

Molecular Diagnostic Assays, Nonclinical Model Development, COVID-19 Vaccine, Advanced Manufacturing Technologies

3/9/20

Broad Agency Announcement (BAA)

BARDA

not specified

White papers due by 10/31/20

Biomedical, Devices

Diagnostic assays, COVID-19 Vaccine, COVID-19 Therapeutics, Immunomodulators or therapeutics targeting lung repair, Pre-exposure and post-exposure prophylaxis, Respiratory protective devices, Ventilators, Advanced Manufacturing Technologies

3/9/20

Department of Energy RFI

Department of Energy

n/a

rolling

Computation, Facilities, Physical Sciences

Ideas to leverage DOE user facilities, computational resources, and infrastructure to assist with the COVID-19 response

3/12/20

COVID-19 Open Research Dataset (CORD-19)

Allen Institute for AI

n/a

rolling

Computation, Physical Sciences

Announcing the availability of COVID-19 datasets; new text and data mining techniques sought to help the science community use COVID-19 research data

3/16/20

Notice of Special Interest (NOSI) regarding the Availability of Emergency Competitive Revisions for Research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19)

NIH (NIAID)

Not specified

Open through 3/25/21

Biomedical

NIAID is offering Competitive Revisions to active grants. Viral natural history, pathogenicity, transmission, medical countermeasures, animal models, pre-clinical testing of vaccines and therapeutics. Apply via PA-20-135.

3/25/20

Notice of Special Interest (NOSI) regarding the Availability of Urgent Competitive Revisions for Research on Coronavirus Disease 2019 (COVID-19) and the Causative Virus SARS-CoV-2

NIH (NIGMS)

Not specified

Open through 2/6/21

Biomedical, Public Health

NIGMS is offering Competitive Revisions to active grants. 2019-nCoV data, develop predictive models for the spread of Coronaviruses and related pathogens. Apply via PA-18-935.

2/6/20

Notice of Special Interest (NOSI) regarding the Availability of Administrative Supplements and Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus

NIH (NIDA)

Up to $100,000 direct costs per year

Open through 3/31/21

Biomedical, Public Health

Research collecting and examining data on the risks and outcomes for COVID-19 infection in individuals suffering from substance use disorders. Apply via PA-18-935 or PA-18-591.

3/19/20

Partnerships for Countermeasures against Select Pathogens (R01)

NIH (NIAID)

up to $750,000 direct costs per year

6/29/20

Biomedical

Preclinical development of lead candidate therapeutics/vaccines/related countermeasures, Emerging Infectious Diseases/Pathogens, Product Development Strategy, collaboration with industry

3/11/20

Notice of Special Interest (NOSI): Availability of Administrative Supplements and Revision Supplements on Coronavirus Disease 2019 (COVID-19)

NIH (NHLBI)

Not specified

Open through 10/6/20

Biomedical

Host response, associations with heart/lung/blood (HLB) diseases, potential impacts on transfusion safety, clinical outcomes of infected individuals. Apply via PA-18-935 or PA-18-591.

3/17/20

Dear Colleague Letter on the Coronavirus Disease 2019 (COVID-19)

NSF

Up to $200,000

rolling

Computation, Biological Sciences, Physical Sciences, Social Sciences

Non-medical and non-clinical-care research, modeling understanding the spread of COVID-19, virus transmission and prevention, processes and actions to address this global challenge. Apply through existing funding opportunities and use the Rapid Response Research (RAPID) funding mechanism.

3/4/20

Dear Colleague Letter: Provisioning Advanced Cyberinfrastructure to Further Research on the Coronavirus Disease 2019 (COVID-19)

NSF

Not specified

rolling

Computation, Physical Sciences

Address COVID-19 challenges through data and/or software infrastructure development activities. Apply through the CDS&E or CSSI program and use the Rapid Response Research (RAPID) funding mechanism or supplements.

3/5/20

Health Security & Pandemics Challenge

MIT Solve

$10,000

6/18/20

Technology development, Biomedical, Computation, Physical Sciences

Tech innovations that can slow and track the spread of an emerging outbreak (for example by improving individual hygiene, developing low-cost rapid diagnostics, analyzing data that informs decision making, providing tools that support and protect health workers)

3/5/20

Prototype Development to Combat Novel Coronavirus Disease COVID-19

Department of Defense, via MTEC

Not specified

Enhanced White Papers due 4/15/20

Biomedical, Computation, Technology development

Point-of-care diagnostics, Prophylactic(s)/Therapeutic(s), Disease predictive modeling that may include social media and artificial intelligence (AI) parameter decision tools, Patient monitoring/tracking/management system for in-home or non-hospital environment, patient tele-health services

3/15/20

Epidemic Preparedness: COVID-19 funding call

Wellcome Trust (UK)

up to $2.3 M

not currently accepting new submissions; check back for updates

Biomedical, Public Health

Clinical research, Treatments, Pathogenesis, Epidemiology, Social sciences and ethics

2/13/20